First-line chemotherapy for ovarian cancer - the controversy continues.

Br J Cancer · 2002 · PMC2376182 · PMID 12373592

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

of borderline significanceP =0.06so close (0.05 < p ≤ 0.1)

As pointed out by Sandercock et al , a pooling of the overall data utilising the random effects model does suggest a benefit for paclitaxel-platinum of borderline significance (hazard ratio for progression free survival of 0.84, 95% confidence intervals of 0.70 and 1.01, P =0.06).

also in 1,491 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.